NCT05158335 - Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of MBX 2109 in Healthy Adult Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 10, 2021

Primary Completion Date

June 20, 2023

Study Completion Date

June 20, 2023

Conditions

Healthy

Interventions

DRUG

MBX 2109 (Part A)

Single ascending SC dose of MBX 2109: 50 µg, 150 µg, 300 µg, 460 µg, 600 µg

DRUG

MBX 2109 (Part B)

Repeated ascending SC doses of MBX 2109: 200 µg, 300 µg, 460 µg, 600 µg, 900 µg

DRUG

Placebo

Single SC dose or repeated SC doses of placebo.

Trial Locations (2)

Labcorp Drug Development: Clinical Research Unit, Madison

Labcorp Drug Development: Clinical Research Unit, Dallas